Claims
- 1. A method for treating pathologies in which LHRH analog administration is beneficial, comprising administering to a subject in need thereof an effective amount of a polyethylene glycol-luteinizing hormone releasing hormone (LHRH) analog conjugate having a polyethylene glycol (PEG) moiety covalently bound to a serine residue of LHRH analog, wherein said conjugate is capable of hydrolysis to release said LHRH analog.
- 2. The method according to claim 1, wherein said PEG moiety is covalently bound to said serine residue of LHRH analog via a bifunctional linker molecule.
- 3. The method according to claim 2, wherein said bifunctional linker molecule is a heterobifunctional linker molecule.
- 4. The method according to claim 3, wherein said bifunctional linker molecule forms an ester with said serine residue of LHRH analog.
- 5. The method according to claim 3, wherein said heterobifunctional linker molecule is an amino acid.
- 6. The method according to claim 5, wherein said heterobifunctional linker molecule is glycine.
- 7. The method according to claim 1, wherein said LHRH analog is a LHRH agonist.
- 8. The method according to claim 1, wherein said LHRH analog is a LHRH antagonist.
- 9. The method according to claim 8, wherein said LHRH antagonist is antide.
CROSS REFERENCE TO RELATED APPLICATION
[0001] The present application claims the benefit of U.S. provisional application No. 60/083,340, filed Apr. 28, 1998, the entire contents of which are herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60083340 |
Apr 1998 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09968134 |
Sep 2001 |
US |
Child |
10184126 |
Jun 2002 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US99/09160 |
Apr 1999 |
US |
Child |
09968134 |
Sep 2001 |
US |